Difficult-to-control Type 2 diabetes (T2D) may be in the clutches of Hypercortisolism


Ease the grip with Korlym

View Efficacy
Up to 10% of patients with difficult-to-control type 2 diabetes (T2D) may have hyperglycemia secondary to endogenous hypercortisolism.

may have hyperglycemia secondary to endogenous hypercortisolism.1-3

1 in 10 people icon.
Korlym mechanism of action.

Korlym is the only therapy specifically indicated to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing syndrome.4

Korlym is a reversible glucocorticoid receptor antagonist that modulates cortisol activity to improve glucose control.5

Glucometer icon.
Improved Glucose Control

60% of patients experienced a ≥25% reduction from baseline in AUCglucose by Week 24/ET (P<0.001) in the pivotal clinical trial6

See Improvements
Weight and depression icon.
Mean reductions in HbA1c and T2D medications

In a pivotal trial, patients on Korlym achieved a significant 1.1% reduction in HbA1c by Week 24/ET (n=25; P<0.001), and some patients were able to reduce their T2D medications6

View Reductions
Weight and depression icon.
Reductions in weight and depression

Patients on Korlym experienced a significant 5.7% reduction in weight, and some patients improved to minimal depression by Week 24/ET (P<0.001)6*

View Reductions

ET, early termination.

Because of the variability in clinical presentation and variability of response in the open-label trial, it is uncertain whether the change in body weight or psychiatric symptoms could be ascribed to the effects of Korlym.4

For more information about Korlym

  1. Chiodini I, Torlontano M, Scillitani A, et al. Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients. Eur J Endocrinol. 2005;153(6):837-844. doi:10.1530/eje.1.02045
  2. Catargi B, Rigalleau V, Poussin A, et al. Occult Cushing’s syndrome in type-2 diabetes. J Clin Endocrinol Metab. 2003;88(12):5808-5813. doi:10.1210/jc.2003-030254
  3. Costa DS, Conceição FL, Leite NC, Ferreira MT, Salles GF, Cardoso CR. Prevalence of subclinical hypercortisolism in type 2 diabetic patients from the Rio de Janeiro Type 2 Diabetes Cohort Study. J Diabetes Complications. 2016;30(6):1032-1038. doi:10.1016/j.jdiacomp.2016.05.006
  4. Korlym Prescribing Information. Corcept Therapeutics, Inc; 2019.
  5. Bourgeois S, Pfahl M, Baulieu EE. DNA binding properties of glucocorticosteroid receptors bound to the steroid antagonist RU-486. EMBO J. 1984;3(4):751-755. doi:10.1002/j.1460-2075.1984.tb01879.x
  6. Fleseriu M, Biller BMK, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97(6):2039-2049. doi:10.1210/jc.2011-3350